Monoclonal antibodies have proved to be extremely valuable additions to conventional treatment for rheumatic diseases. However, despite the general trend towards “humanisation”, these drugs remain immunogenic in clinical settings, baffling drug developers. In principle, humanised and fully human monoclonal antibodies are “self” immunoglobulins and should be tolerated. In this overview, the factors that may influence this process, the nature of immunogenicity and methods to analyse and modify potential immunogenicity are discussed. Finally, novel approaches to “re-induce” immunological tolerance to these proteins, including gene therapy and the recognition of unique regulatory epitopes, are outlined.
Statistics from Altmetric.com
Funding Research supported by grants from the NIH (RO1 HL061883, RO1 AI035622, RO1DK068343, R43HL08834 and from the Juvenile Diabetes Foundation.
Competing interests DWS is on the Scientific Advisory Board of EpiVax, Inc. ASDG is CEO and majority stockholder in EpiVax. This author acknowledges that there is a potential conflict of interest related to her relationship with EpiVax and attests that the work contained in this research report is free of any bias that might be associated with the commercial goals of the company.
Provenance and Peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.